ADC Therapeutics Balance Sheet Health
Financial Health criteria checks 1/6
ADC Therapeutics tiene unos fondos propios totales de $-54.2M y una deuda total de $424.3M, lo que sitúa su ratio deuda/fondos propios en -783.1%. Sus activos y pasivos totales son $466.9M y $521.1M respectivamente.
Key information
-280.8%
Debt to equity ratio
US$416.30m
Debt
| Interest coverage ratio | n/a |
| Cash | US$278.60m |
| Equity | -US$148.25m |
| Total liabilities | US$503.03m |
| Total assets | US$354.78m |
Recent financial health updates
Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16
Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?
Jun 22Recent updates
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
Sep 16ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Sep 09ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M
Aug 09Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts
Jul 21Sobi to pay ADC Therapeutics $55M upfront to license Zynlonta in Europe, other regions
Jul 08ADC Therapeutics begins dosing in study of Zynlonta combo for blood cancer subtype
Jun 29Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?
Jun 22ADC Therapeutics SA (NYSE:ADCT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 06Growth Investors: Industry Analysts Just Upgraded Their ADC Therapeutics SA (NYSE:ADCT) Revenue Forecasts By 21%
Mar 05Financial Position Analysis
Pasivos a corto plazo: ADCT tiene fondos propios negativos, que es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.
Pasivo a largo plazo: ADCT tiene fondos propios negativos, lo que es una situación más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.
Debt to Equity History and Analysis
Nivel de deuda: ADCT tiene fondos propios negativos, que es una situación más grave que un alto nivel de endeudamiento.
Reducción de la deuda: ADCT's tiene fondos propios negativos, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Cash runway estable: ADCT tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si ADCT tiene suficiente margen de liquidez en caso de que su flujo de caja libre siga creciendo o disminuyendo en función de las tasas históricas.